A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors
Sponsor: Millennium Pharmaceuticals, Inc.
Listed as NCT03486314, this PHASE1 trial focuses on Advanced Solid Neoplasm and remains completed. Sponsored by Millennium Pharmaceuticals, Inc., it has been updated 14 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2021 — May 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Jun 2019 [monthly]
Recruiting PHASE1
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .